Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

On December27, 2018, Axsome Therapeutics,Inc. issued a press release providing an update on the status of its clinical product candidates, AXS-05, AXS-07, and AXS-12.

The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number

Description

99.1

Press release dated December27, 2018.

Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a18-42129_1ex99d1.htm EX-99.1 Exhibit 99.1     Axsome Therapeutics Provides Year End 2018 Clinical Update   FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy   Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019   Phase 3 results of AXS-05 in treatment resistant depression on track for 1Q 2019   Phase 3 trial of AXS-07 in acute migraine on track to start in 1Q 2019   NEW YORK,…
To view the full exhibit click here

About Axsome Therapeutics,Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

An ad to help with our costs